Who
Chirfi Guindo
EVP, Access, Policy & Comms
Company insider
Files Form 4 as: EVP, Access, Policy & Comms, Merck & Company; Director, Beam Therapeutics; Head of Glob Prod Strat & Com, Biogen.
In numbers
- Trades disclosed
- 90
- Buys
- 0
- Sells
- 6
- Bought
- $0
- Sold
- $17.7M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 1 Dec 2017
- Last trade
- 13 Aug 2026
- Last filed
- 13 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 13 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.4M10,000 at $135.00 | filing |
| 13 Aug 2026filed 13 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.4M10,000 at $135.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $2.0M15,000 at $131.00 | filing |
| 6 Aug 2026filed 7 Aug 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $2.0M15,000 at $131.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | BEAM Beam Therapeuticsoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —19,676 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,628 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,402 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —6,628 at $0.00 | filing |
| 5 May 2026filed 7 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —19,402 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $216K1,967 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $107K969 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,967 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & Companyoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —1,967 at $0.00 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code M | $216K1,967 at $110.03 | filing |
| 29 Apr 2026filed 1 May 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Code F | $107K969 at $110.03 | filing |
| 12 Feb 2026filed 12 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M10,000 at $121.46 | filing |
| 12 Feb 2026filed 12 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M10,000 at $121.46 | filing |
| 9 Feb 2026filed 9 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M10,000 at $118.41 | filing |
| 9 Feb 2026filed 9 Feb 2026 | MRK Merck & CompanyPharmaceuticals | SEC FORM 4 Sold | $1.2M10,000 at $118.41 | filing |
News
Moderna, Merck shares fall on eagerly anticipated cancer vaccine resultsMRK · biopharmadive.com · 22 Oct 2026Merck & Co., Inc. $MRK Stock Sold by Smith Chas P & Associates PA CpasMRK · dailypolitical.com · 22 Oct 2026Merck's KEYTRUDA Plus Padcev Wins EU Approval For Muscle-Invasive Bladder CancerMRK · rttnews.com · 21 Oct 2026
0 headlines in the last 90 days name Chirfi Guindo; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.